The largest database of trusted experimental protocols

5 protocols using tofacitinib citrate

1

Mesothelin-targeted Combination Therapy in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Msl transgenic mice, which have knock-in of human mesothelin ortholog into the murine mesothelin locus such that human mesothelin is expressed in the native distribution, were engineered and bred as described in (35 (link)). Mice (Mslnki/+) were treated with tofacitinib (25 mg/kg, 200 µL volume, twice daily by OG, days 1-6) plus LMB-100 (3.5 mg/kg IV, 200 µL volume, Days 4 and 6), oral vehicle (200 µL OG, days 1-6) plus LMB-100, or oral vehicle plus IV PBS (200 µL volume IV, Days 4 and 6). Tofacitinib citrate was purchased from SelleckChem (product S5001), dissolved in DMSO to 250 mg/mL for storage, then diluted into 0.5% methylcellulose, followed by 0.05% Tween20 and PBS just before use. LMB-100 iTox was manufactured by Roche and provided for these studies through a Collaborative Research and Development Agreement. Animals were euthanized 24 hours after last treatment. Tissue specimens were fixed in 10% neutral buffered formalin solution for 48-72 h at RT (HT501128, Sigma-Aldrich, USA), then sent to Molecular Histotechnology Laboratory (MHL) Core facility for all histologic studies. Analysis and quantification were performed by a trained veterinary pathologist affiliated with the MHL Core using criteria described in Supplementary Methods.
+ Open protocol
+ Expand
2

Kinase Inhibitors and Interferon-gamma Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following inhibitors were used: Crizotinib (PF-02341066) (Selleckchem S106), Ceritinib (LDK378) (Selleckchem S7083), Alectinib (CH5424802) (Selleckchem S2762), Lorlatinib (PF-6463922) (Selleckchem S7536), Selumetinib (AZD6244) (Selleckchem S1008), Trametinib (GSK1120212) (Selleckchem S2673), Tofacitinib Citrate (CP-690550) (Selleckchem S5001), AZD1480 (Selleckchem S2162), Rapamycin (Selleckchem S1039), LY294002 (Selleckchem S1105), JNK-IN-8 (Selleckchem S4901), Ro-31-8220 (Selleckchem 7207), AZD5363 (Selleckchem S8017), Ipatasertib (Selleckchem S2808), SCH772984 (Selleckchem S7101), Ulixertinib (Selleckchem S7854). BKM120 and Tepp-46 were kind gifts from Dr. Thomas Craig, NCI, Bethesda, Maryland, USA; recombinant human interferon-gamma, IFNγ (BioLegend 570208).
+ Open protocol
+ Expand
3

Modulating Cytokine Production in SFMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
SFMCs were seeded in a density of 2 million cells/mL. SFMCs were cultured with pembrolizumab at 5 μg/mL with or without the TNFα inhibitor adalimumab (Humira™, Abbvie, North Chicago, IL, USA) at 5 μg/mL, the IL-6R inhibitor tocilizumab (RoActemra™, Roche, Hvidovre, Denmark) at 5 μg/mL or the Janus kinase (JAK) inhibitors tofacitinib citrate at 200 nM (Selleckchem, Munich, Germany), or baricitinib citrate at 200 nM (Selleckchem) as described previously [25 (link), 26 (link)]. In all experiments, negative controls included untreated cells or the vehicle dimethyl sulfoxide (DMSO). Cell cultures treated with LPS at 100 ng/mL were included as positive controls for cytokine expression. After 48 h of incubation, cell suspensions were transferred to Eppendorf tubes and centrifuged at 300 × g for 10 min at RT. The supernatants were collected and stored until later analysis for MCP-1 production.
+ Open protocol
+ Expand
4

Kinase Inhibitors and Interferon-gamma Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following inhibitors were used: Crizotinib (PF-02341066) (Selleckchem S106), Ceritinib (LDK378) (Selleckchem S7083), Alectinib (CH5424802) (Selleckchem S2762), Lorlatinib (PF-6463922) (Selleckchem S7536), Selumetinib (AZD6244) (Selleckchem S1008), Trametinib (GSK1120212) (Selleckchem S2673), Tofacitinib Citrate (CP-690550) (Selleckchem S5001), AZD1480 (Selleckchem S2162), Rapamycin (Selleckchem S1039), LY294002 (Selleckchem S1105), JNK-IN-8 (Selleckchem S4901), Ro-31-8220 (Selleckchem 7207), AZD5363 (Selleckchem S8017), Ipatasertib (Selleckchem S2808), SCH772984 (Selleckchem S7101), Ulixertinib (Selleckchem S7854). BKM120 and Tepp-46 were kind gifts from Dr. Thomas Craig, NCI, Bethesda, Maryland, USA; recombinant human interferon-gamma, IFNγ (BioLegend 570208).
+ Open protocol
+ Expand
5

Potent LRRK2, JAK1/2 Inhibitors Profiled

Check if the same lab product or an alternative is used in the 5 most similar protocols
All compounds were > 98.5% pure as assessed by LC/MS and NMR analysis. The small molecule LRRK2 inhibitor MLi2 was synthesized for this study using the previously described strategy by Pharmaron, Inc. [35 (link)]. AZD1480 is an ATP-competitive JAK1/2 inhibitor with an IC50 of 0.26 nM (Selleckchem, Inc). Tofacitinib citrate (CP-690550, Selleckchem, Inc) is an inhibitor for JAKs with an IC50 of 1 nM, 20 nM and 112 nM IC50 against JAK3, JAK2, and JAK1, respectively. Ruxolitinib (Selleckchem, Inc) is a selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM, respectively.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!